Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON PHARMING GROUP N.V. (PHAR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 30, 2026, the Company reported second quarter earnings, including revenue of $90.2 million, reflecting a 3.2% year over year decline. Further, the Company reported a 10% revenue decline for RUCONEST. The Company stated, among other things, that “the year-over-year decline reflected... temporary inventory normalization." The Company also cut its full year revenue guidance approximately $30 million at the midpoint to $375 to $395 million and stated “[a]t the midpoint of our guidance range, RUCONEST U.S. revenue is expected to decline approximately 3% for the full year."
